Tonix Pharmaceuticals Holding Corp. has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the higher tier is expected to begin at the open of market on March 3, 2026, under the existing ticker symbol "TNXP." The move reflects the company's compliance with the Nasdaq Global Select Market's more stringent financial and corporate governance requirements.
Management described the uplisting as an important milestone as the company continues to focus on growth and shareholder value creation. The transfer is expected to enhance institutional visibility, liquidity and broader market recognition for the biotechnology firm. This development comes as Tonix Pharmaceuticals operates as a fully-integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments in areas of high unmet medical need.
The company's recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), represents the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition to its CNS portfolio, which includes TNX-2900 that is Phase 2 ready for the treatment of Prader-Willi syndrome, Tonix is advancing a pipeline of immunology programs. These include monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. It is important to note that Tonix's product development candidates are investigational new drugs or biologics whose efficacy and safety have not been established and have not been approved for any indication.
The Nasdaq Global Select Market listing represents a significant step for Tonix Pharmaceuticals as it seeks to expand its market presence and investor base. The higher listing tier typically attracts more institutional investors and may provide greater stability for the company's stock. For investors, this development signals Tonix's commitment to maintaining rigorous financial standards and corporate governance practices while pursuing growth in the competitive biotechnology sector.
Additional information about the company is available through its newsroom at https://ibn.fm/TNXP. The original announcement about the Nasdaq listing transfer can be viewed at https://ibn.fm/uDmmW. The move to a more prestigious market tier comes at a time when the company is expanding its commercial operations and advancing multiple clinical programs across neurological and immunological disorders.
